Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Coridon has entered into a research collaboration agreement with the Ohio State University to advance its Epstein Barr Virus (EBV) project to prevent lymphomas.
Subscribe to our email newsletter
The company’s major shareholder Allied Healthcare Group (AHZ) is working with Coridon founder Ian Frazer to assist in the commercialisation of his work.
Coridon’s technology has been developed to stimulate not only a strong antibody response but also a cellular immune response and is particularly suited to the development of therapeutic vaccines.
The company is also working with the University of Washington on the company’s Herpes Simplex Virus 2 (HSV-2) vaccine.
Coridon plans to start Phase I human trials of the vaccine in 2012.
CEO Neil Finlayson said this technology is being applied to the development of DNA vaccines for a range of infectious diseases and cancer.
"We are very fortunate to be able to work with global leaders on this project and will look at expanding our collaboration as appropriate," Finlayson said.